Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 204 of the 206 references it cites were found in a registry or an index; 68 of the 244 sources its claims cite were checked for support.
Abstract
Objective The aim was to develop clinical practice guidelines on hypertriglyceridemia. Participants The Task Force included a chair selected by The Endocrine Society Clinical Guidelines Subcommittee (CGS), five additional experts in the field, and a methodologist. The authors received no corporate funding or remuneration. Consensus process Consensus was guided by systematic reviews of evidence, e-mail discussion, conference calls, and one in-person meeting. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. Conclusions The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150-999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hypertriglyceridemia (triglycerides of > 1000 mg/dl) be considered a risk for pancreatitis. The Task Force also recommends that patients with hypertriglyceridemia be evaluated for secondary causes of hyperlipidemia and that subjects with primary hypertriglyceridemia be evaluated for family history of dyslipidemia and cardiovascular disease. The Task Force recommends that the treatment goal in patients with moderate hypertriglyceridemia be a non-high-density lipoprotein chole…
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends evaluating and treating hypertriglyceridemia with fasting triglyceride measurement, secondary-cause workup, lifestyle therapy for mild-to-moderate elevations, and combined diet plus drug therapy for severe/very severe hypertriglyceridemia to prevent pancreatitis. It also concludes that triglycerides are associated with cardiovascular risk but whether they are causal remains uncertain.
Key findings
- The guideline recommends screening adults with a fasting lipid panel at least every 5 yr (1/QQEE), basing hypertriglyceridemia diagnosis on fasting rather than nonfasting triglycerides (1/QQQE), and against routine lipoprotein particle heterogeneity measurement (1/QQEE).
- It defines moderate hypertriglyceridemia as 200–999 mg/dl, severe as 1000–1999 mg/dl, and very severe as ≥2000 mg/dl; for severe/very severe hypertriglyceridemia (>1000 mg/dl), it recommends combining dietary fat and simple carbohydrate reduction with drug treatment to reduce pancreatitis risk (1/QQQQ), with fibrate as first-line for triglyceride-induced pancreatitis (1/QQQE).
- Lifestyle therapy is recommended initially for mild-to-moderate hypertriglyceridemia (1/QQEE); for moderate hypertriglyceridemia, the treatment goal is a non-HDL cholesterol level in agreement with NCEP ATP guidelines (1/QQEE); statins should not be used as monotherapy for severe or very severe hypertriglyceridemia but may be useful for moderate hypertriglyceridemia to modify cardiovascular risk (1/QQEE).
- In NHANES 1999–2004, 33% of nearly 6000 participants had serum triglycerides ≥150 mg/dl (42% among those aged ≥60 yr); about 14% had 150–200 mg/dl, 16% had 200–500 mg/dl, and about 2% had >500 mg/dl. Meta-analytic estimates included an adjusted odds ratio of 1.72 (95% CI, 1.56–1.90) for coronary heart disease comparing top vs bottom triglyceride tertiles, and an ERFC hazard ratio of 1.37 (95% CI, 1.31–1.42) after adjustment for nonlipid factors, reduced to 0.99 (95% CI, 0.94–1.05) after adjustment for HDL and non-HDL cholesterol.
Methods
- The Task Force followed the GRADE approach: strong recommendations use “we recommend” and number 1; weak recommendations use “we suggest” and number 2; evidence quality is denoted QEEE (very low), QQEE (low), QQQE (moderate), and QQQQ (high).
- The guideline was developed by a chair selected by The Endocrine Society Clinical Guidelines Subcommittee, five additional experts, and a methodologist; evidence included observational/epidemiological studies and a systematic review/meta-analysis commissioned by The Endocrine Society.
- Funding was derived solely from The Endocrine Society, and the Task Force received no corporate funding or remuneration.
Limitations
- The Task Force states that it acknowledges the observational nature of the available evidence and dependence on epidemiological studies, and that it made several strong recommendations based on assumptions about patients’ values and preferences.
- The paper states that whether serum triglycerides are causally related to atherosclerosis remains to be elucidated, that elevated triglycerides may sometimes be a marker rather than a causal factor, and that there is a lack of clear human data showing triglyceride reductions reduce cardiovascular disease.
- Stated limitations of specific evidence include lack of standardization and reference levels for nonfasting triglycerides, and for the Copenhagen City Heart Study analysis, a small number of subjects with high triglycerides, no adjustment for HDL cholesterol, and lack of fasting triglyceride levels for comparison.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Valid · 24 Not valid · 106 Not checked · 100 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Epidemiological studies vary as to the independent association between large or small LDL and atherosclerotic cardiovascular disease (30).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Partly supportedcites [30] Austin, 1990, Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk., Circulation sourceExperimental — accuracy not yet measured
The introduction (p. 495) reports that the small, dense LDL phenotype was associated with increased myocardial infarction risk, consistent with two previous studies. But the paper does not say that epidemiological studies vary in their findings about an independent association of large or small LDL with cardiovascular disease. Its multivariate analysis examines associations with LDL phenotype, not independent associations with disease. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Prospective multivariate studies demonstrate that large LDL predicts atherosclerosis and coronary heart disease (35,38,39).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Not checked — no full text of the sourcecites [35] Sacks, 2003, Low density lipoprotein and cardiovascular disease: a reappraisal. (Clinical Review 163)., J Clin Endocrinol Metab source
- Partly supportedcites [38] Mora, 2009, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women., Circulation sourceExperimental — accuracy not yet measured
The Results (Association of NMR Lipoproteins, Lipids, and Apolipoproteins with CVD; page unavailable) report that large LDL particles were significantly associated with incident cardiovascular disease in women when all nine particle subclasses were included in the model. They were not associated with cardiovascular disease in the separate adjusted model. The paper does not establish that large LDL specifically predicts atherosclerosis or coronary heart disease. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [39] Campos, 2001, Low density lipoprotein size, pravastatin treatment, and coronary events., JAMA source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Several reports also show that measurement of apoB is superior to measurement of LDL or even non-HDL cholesterol as an indicator of global CVD risk (40,41).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Not checked — no full text of the sourcecites [40] de Graaf, 2008, A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias., Nat Clin Pract Endocrinol Metab source
- Supportedcites [41] Holewijn, 2010, Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk., J Intern Med source
The Discussion reports that, in this population-based sample, apoB identified people with a compromised cardiovascular risk profile more effectively than non-HDL cholesterol, while LDL cholesterol was least effective. It also reports significantly greater discrimination of prevalent CVD for apoB than for non-HDL cholesterol. The finding is based on this cohort; the authors note that a cited meta-analysis found no difference between apoB and non-HDL cholesterol. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several prospective studies suggest that circulating levels of small, dense LDL particles are better predictors of coronary atherosclerosis, carotid atherosclerosis, and response to therapy than are levels of large, buoyant LDL particles (28,(31)(32)(33).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Partly supportedcites [28] Zambon, 1999, Evidence for a new pathophysiological mechanism for coronary artery regression: hepatic lipase-mediated changes in LDL density., Circulation sourceExperimental — accuracy not yet measured
The Abstract reports prospective associations between LDL size or density and coronary artery disease, and says patients with small, dense LDL responded better to therapy than those with large, buoyant LDL. The Results link changes in LDL buoyancy to changes in coronary stenosis. The cited paper does not address carotid atherosclerosis, so it does not support that part of the claim. Page numbers are unavailable in our copy. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [31] St-Pierre, 2005, Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study., Arterioscler Thromb Vasc Biol source
- Not checked — no full text of the sourcecites [32] Mora, 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)., Atherosclerosis source
- Partly supportedcites [33] Musunuru, 2009, Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk., Arterioscler Thromb Vasc Biol sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that small and medium LDL particle levels were associated with cardiovascular disease, whereas large LDL particle levels were not significantly related; it also says this pattern agrees with prospective cohorts including a study of carotid atherosclerosis. It does not establish that small, dense LDL levels predict response to therapy better than large LDL levels. Instead, the Discussion proposes evaluating lipoprotein measures in treatment studies as future work. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Prospective studies have indicated that, compared with fasting levels, nonfasting serum triglyceride levels may be a better or similar predictor of CVD events in the general population (15-18).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.2. Evidence
What the sources say
- Not checked — no full text of the sourcecites [15] Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women., JAMA source
- Not checked — no full text of the sourcecites [16] Bansal, 2007, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women., JAMA source
- Supportedcites [17] Mora, 2008, Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events., Circulation source
The paper’s introductory passage says three studies suggested that nonfasting triglycerides may predict CVD events better than or similarly to fasting levels. Its Results also report a stronger association for nonfasting triglycerides in its prospective cohort of initially healthy women. No page number is available in our copy. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [18] Stalenhoef, 2008, Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small, dense LDL., Curr Opin Lipidol source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
149 more claims · 26 with their cited sources checked
Create a free account to see all 283 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 53
- It may state two separate claims as one. 94
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HTG may result from impaired clearance of TRLs, most often due to pathogenic variants in the lipolytic pathway, ranging from monogenic defects in LPL gene or its cofactors (APOC2, APOA5, LMF1, and GPIHBP1) to polygenic susceptibility, and may be exacerbated by secondary factors such as diabetes, obesity, alcohol use, and certain medications [5, 6].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current management strategies for HTG and mixed dyslipidemia provide limited and inconsistent benefits in TG lowering and cardiovascular outcomes, underscoring the need for more effective and durable approaches targeting TRL and apoB-containing lipoproteins (Filtz et al., 2024; Berglund et al., 2012; Chapman et al., 2011).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Berglund et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A delay in diagnosis may place patients at an increased risk for acute pancreatitis.11”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [11]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
From Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome (2019) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Acute pancreatitis can lead to chronic pancreatitis, 10,11 signs of exocrine or endocrine pancreatic insufficiency, including pancreatic (type 3c) diabetes, 12 and can be fatal.”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.1. Evidence
“Of subjects with hypertriglyceridemia, about 14% had mild hypertriglyceridemia (150 -200 mg/dl), whereas 16% had triglyceride levels of 200 -500 mg/dl, and about 2% had levels above 500 mg/dl.”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.1. Evidence
“In the National Health and Nutrition Examination Survey (NHANES), 1999 -2004, 33% of the nearly 6000 participants (37% men, 30% women) had serum triglycerides of at least 150 mg/dl (Ն1.7 mmol/liter) (5).”
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · cited 7×
“Cosponsoring Associations: American Heart Association, European Society of Endocrinology.”
InfluentialDetection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group (1).”
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Research works printed but not linked: 2
- Assmann, 1993, Results and conclusions of the prospective cardiovascular Munster (PROCAM) study, 19
- Brunzell, 2001, Familial lipoprotein lipase deficiency, ApoC-II deficiency, and hepatic lipase deficiency, 2789
Cited by
Items 601–700 of 886
Shah, M. A., Sharma, A., Ayyad, M., Swartz, E., Jafrani, D., & Gala, D. (2024) · Cureus · doi:10.7759/cureus.67091 · Cited by 5
“Hypertriglyceridemia is categorized as mild to moderate when levels are greater than 150 mg/dL-499 mg/dL, whereas severe hypertriglyceridemia is categorized by levels surpassing 500 mg/dL [2].”
BackgroundKapat, A., Murmu, R., Mandal, S., Biswas, K., Bhakta, S., & Mandal, A. K. (2024) · Cureus · doi:10.7759/cureus.67936 · Cited by 2
“The Endocrine Society Clinical Practice Guidelines published in 2010 and the European Society Consensus Panel in 2012 opined a cut-off of more than 150 mg/dL to be hypertriglyceridemia [15-16].”
BackgroundMethodThanh, N. H., Duong, T. V., Huyen, N. T., & Hai, P. D. (2024) · Turkish Journal of Emergency Medicine · doi:10.4103/tjem.tjem_27_24 · Cited by 2
High‐Speed Centrifugation Fails to Mitigate Severe Lipemic Interference in D‐dimer Measurement
Xu, X., Cai, S., Xue, J., et al. (2025) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14479 · Cited by 2
Bajaj, A., Oral, E. A., Brown, A. S., Gaudet, D., Alexander, V. J., Karwatowska‐Prokopczuk, E., & Baum, S. J. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101352 · Cited by 2
“However, in recent clinical trials, APOC3 -targeted oligonucleotide therapies reduce TG levels and appear to decrease acute pancreatitis incidence in patients with FCS [1,11,15 – 18].”
Nutritional Epigenome and Metabolic Syndrome
Lee, H., & Herceg, Z. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805388-1.00030-4 · Cited by 2
Skoczyńska, A., Wawrzynowicz‐Syczewska, M., Barlik-Rysa, M., Danik, A., Różański, J., Filipiak, K. J., & Cybulska, B. (2020) · Folia Cardiologica · doi:10.5603/fc.2020.0001 · Cited by 1
Progress in diagnosis and treatment of hypertriglyceridemic acute pancreatitis
Sun, Y. T. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i24.1223 · Cited by 2
Over-the-counter fish oil use in a county hospital: Medication use evaluation and efficacy analysis
Tatachar, A., Pio, M. Y., Yeung, D., Moss, E., Chow, D. H., Boatright, S. M., Quinones, M. E., Mathew, A., Hulstein, J. L., ADAMS-HUET, B. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.004 · Cited by 2
Pegaspargase Induced Hypertriglyceridemia Resulting in Severe Fatal Pancreatitis
Vyas, N., Companioni, R. A. C., Tiba, M., et al. (2015) · Case Reports in Gastrointestinal Medicine · doi:10.1155/2015/753062 · Cited by 2
“However, triglyceride levels of >1000mg/dL are considered a risk factor for pancreatitis and are categorized under severe hypertriglyceridemia [5]; thus cessation of Pegaspargase should be instituted.”
BackgroundYi, S., Shin, S., & Lee, Y.-J. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007603 · Cited by 2
Yamada, Y., Shima, H., Shibata, H., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26530 · Cited by 2
PREDICTING HYPERTRIGLYCERIDEMIC PANCREATITIS — NOT SO FAST!
Shapiro, M. D., & Fazio, S. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0121 · Cited by 2
Tiwari, A., Mehta, S., Puri, R., et al. (2018) · Asian Journal of Transfusion Science · doi:10.4103/ajts.ajts_86_17 · Cited by 2
“HTG is classified as mi ld (150–199 mg/dL) , moderate (200–999 mg/dL), severe (1000–1999 mg/dl), and very severe (>2000 mg/dL).[1] Primary causes of HTG include mutations in genes encoding lipoprotein lipase and its activator Apo C‐II, while secondary causes comprise diabetes mellitus (DM), hypothyroidism, pregnancy,…”
BackgroundEvaluation of Body Composition in Patients with Psoriasis
Nazik, H., Mülayim, M. K., Saridağ, D. K., et al. (2019) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/1812-2892-jcmk-00659 · Cited by 2
“In addition, a carbohydrate-rich diet increases blood triglyceride levels [16].”
BackgroundPlasmapheresis for the Treatment of Acute Pancreatitis due to Severe Hypertriglyceridemia
Ruiz‐Rodríguez, J. C., Chiscano‐Camón, L., Palmada, C., et al. (2020) · Blood Purification · doi:10.1159/000510647 · Cited by 2
Singh, B., Gowda, A. M., Kaur, P., Guragai, N., Mechineni, A., & Maroules, M. (2021) · Radiology Case Reports · doi:10.1016/j.radcr.2020.12.059 · Cited by 2
“[3] Berglund L , Brunzell JD , Goldberg AC , Goldberg IJ , Sacks F , Murad MH , et al.”
BackgroundZhou, Y., Zhu, J., Wu, H., Deng, Y., & Ji, Q. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01139-2 · Cited by 4
Treating Hypertriglyceridemia-Induced Pancreatitis With Intravenous Insulin and Plasmapheresis
Ng, L. S., Khor, S. Y., & Ng, W. L. (2022) · Cureus · doi:10.7759/cureus.30237 · Cited by 2
“Different treatment modalities including fibrate, fish oil, and heparin have also been implemented to reduce serum triglycerides [9-11].”
BackgroundHyperlipidemic Pancreatitis: Prevalence, Presentation and Outcome
Alamoodi, M. (2016) · Surgical Science · doi:10.4236/ss.2016.71004 · Cited by 2
“3 mmols/l in patients with type I, IV or hyperlipidemia (Fredrickson’s classification) is an identifiable risk factor [3].”
BackgroundMoyamoya Disease with Coexistent Hypertriglyceridemia in Pediatric Patient
Chan, J. T., Rodriguez, F., Sahni, D., et al. (2016) · Case Reports in Endocrinology · doi:10.1155/2016/7974182 · Cited by 2
Undetectable measured serum bicarbonate associated with hypertriglyceridemia-induced pancreatitis
Veltri, N. L., Chan, M., & Awad, S. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.200237 · Cited by 2
Prevalence and treatment of pediatric dyslipidemia
Song, K., Kim, H.-S., & Chae, H. W. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.6.410 · Cited by 2
Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor
Khan, T. Z., Schatz, U., Bornstein, S. R., & Barbir, M. (2021) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2021.19 · Cited by 3
In Reply: Eruptive xanthoma (April 2015)
Abdelghany, M., & Massoud, S. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82c.08002 · Cited by 2
In Reply: Risk of falls (May 2015)
Beegan, L., & Messinger‐Rapport, B. J. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82c.08004 · Cited by 2
Acute Pancreatitis Associated With Metabolic Disorders, Infectious Diseases, or Drugs
Aghdassi, A. A., & Lerch, M. M. (2018) · Wiley eBooks · doi:10.1002/9781119188421.ch24 · Cited by 2
Lee, I., Tong, S., Hatada, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4145645 · Cited by 2
Prise en charge des hypertriglycéridémies sévères
Nouvel, M., Sassolas, A., & Moulin, P. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70531-5 · Cited by 2
A novel rat model of fatty organ degeneration induced by poloxamer 407
Yin, N., Chu, T., Peng, Y., et al. (2019) · Journal of Bio-X Research · doi:10.1097/jbr.0000000000000027 · Cited by 1
Baqi, H. R., & Rostam, S. R. K. (2020) · Kurdistan Journal of Applied Research · doi:10.24017/science.2020.2.5 · Cited by 2
“ranges were calculated for TC below 200 mg/dL, [32], TG below 150 mg/dL [33], HDL-C”
Soyaltın, U. E., BOZKURT, A. B. K., Solmaz, A. E., Hakverdi, G., & Şimşir, İ. Y. (2022) · Ege Tıp Dergisi · doi:10.19161/etd.1209062 · Cited by 1
Insulin Management for Hypertriglyceridemia in Pregnancy
Cheng, D., Ma, J., Kuang, M., Lu, C., Weng, J., Yang, Y., & Xu, X. (2022) · Maternal-Fetal Medicine · doi:10.1097/fm9.0000000000000175 · Cited by 1
Lin, N., Cui, W., Li, X., Chang, J. K., & Xue, X. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1193971 · Cited by 2
Kinsara, A. J., & Sabbour, H. M. (2023) · Medicine · doi:10.1097/md.0000000000035416 · Cited by 1
“[25–29] The majority of surveyed physicians reported using guidelines in their daily practice for the management of dyslipidemia.”
BackgroundHYPERTRIGLYCERIDEMIA AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASES
NURIEVA, L. M., KIM, Z. F., GALYVICH, A. S., & Sadykova, D. I. (2023) · The Bulletin of Contemporary Clinical Medicine · doi:10.20969/vskm.2023.16(4).104-110 · Cited by 2
Application of Lipid Apheresis in Acute Lipogenic Pancreatitis
Yu, Y., Yuan, F., Song, P., Sun, C., Xiong, H., & Song, J. (2024) · Blood Purification · doi:10.1159/000536301 · Cited by 1
Aljabri, B. K., Saber, W., Alzahrani, S., & Dada, A. M. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luae054 · Cited by 1
Muñoz, C., Toro, V. D., Gana, J. C., Harris, P. R., Loureiro, C., & Alberti, G. (2024) · Andes pediatrica · doi:10.32641/andespediatr.v95i2.4967 · Cited by 1
Zhao, W., Wang, Y., Li, J., Chen, T., Yin, D., Dai, H., Yao, Z., & Zhao, S. (2024) · Lipids · doi:10.1002/lipd.12406 · Cited by 1
Nontraditional Lipid Parameters as a Predictor of Cardiovascular Disease Risk in Nepalese Women
Adhikaree, J., Shrestha, R., Bomjan, P., Pokharel, S., Shrestha, A., Siwakoti, A., Acharya, R., Marzo, R. R., Acharya, S., Pokhrel, R., et al. (2024) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_179_23 · Cited by 2
“[22]”
Li, X., Zhang, B., Liang, X.-R., Han, Y.-Y., Cheng, M.-H., Wei, M., Cao, K., Chen, X., Chen, M., Duan, J., et al. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02088-6 · Cited by 2
Wang, T., Cao, F., He, J., Zhu, L., Yang, X., Ma, S., Zhu, Q., Li, Y., Yang, C., Liu, J., et al. (2025) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2025.10864/2024 · Cited by 2
Trends and prevalence of severe hypertriglyceridemia in Pakistan: A 5-year analysis (2019-2023)
Ain, Q., Khan, M., Nawaz, A., Batool, H., Khan, M. I., Ajmal, M., & Sadiq, F. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.02.009 · Cited by 7
Mansour, A., & Ghasemzade, S. (2025) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514251323826 · Cited by 1
“…as follows: normal is less than 150 mg/dL, mild is between 150 and 199 mg/dL, moderate is between 200 and 999 mg/dL, severe is between 1000 and 1999 mg/dL, and very severe exceeds 2000 mg/dL. 18 While moderate hypertriglyceridemia is common during DKA, very severe hypertriglyceridemia is uncommon.”
Liu, J., Liang, C., Yan, W., Zhang, Y., Pan, Y., Yang, Y., Zhang, F., Liu, X., & Jin, L. (2025) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.70032 · Cited by 1
“Serum TG up to 1000 mg/dL is necessary for the diagnosis of HTGP in the clinic [19, 20] and is also necessary for the induction of HTGP.”
Severe hypertriglyceridaemia and lipaemia retinalis in a child presenting with diabetic ketoacidosis
Kimber, K., Crawley, E., & Jones, S. (2025) · Diabetic Medicine · doi:10.1111/dme.70026 · Cited by 1
Clinical Management of Dyslipidemia in Infants and Toddlers
Kelley, J. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01305-y · Cited by 1
2024 Taiwan clinical practice guideline for diabetic kidney disease – an executive summary
Su, S., Chang, T.-C., Chiu, Y., Chu, C., Hsu, Y., Kuo, C., Lee, C., Lin, M., Lin, C., Lin, Y.-F., et al. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.08.020 · Cited by 3
Thacker, E., Wageh, J., & Smith, S. E. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf347 · Cited by 2
Zheng, R., Zhang, Z., Yan, J., et al. (2026) · International Medical Case Reports Journal · doi:10.2147/imcrj.s581484 · Cited by 1
Cho, E. J., Lee, J. H., You, G.-R., Chung, M., Kim, G., Park, S., Haque, M., Liddle, R. A., & Park, C. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.04.015 · Cited by 2
Update on Investigation and Management of Dyslipidaemias and Cardiovascular Disease Risk
Antwi, K., Luvai, A., Downie, P., Ghani, A., Maple, M., & Mbagaya, W. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm54141 · Cited by 1
Efficacy and safety of olezarsen in patients with vs without baseline fibrate use
Wang, A. Z., Alexander, V. J., Prohaska, T. A., Ran, X., Goodrich, E. L., Murphy, S. A., Zimerman, A., Moura, F. A., Kang, Y. M., Nordestgaard, B. G., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.001 · Cited by 1
Yang, Y. L., & Li, Y. (2026) · Archives of Medical Science · doi:10.5114/aoms/221198 · Cited by 1
“Tri-glyceride levels were stratified in accordance with the NCEP ATP III criteria [33].”
y Ambientales, U. D. C. A., Galeano, A. M. A., Hernández, D. F. B., y Ambientales, U. D. C. A., Fierro, L. A. R., y Ambientales, U. D. C. A., Leyva, A. M. S., y Ambientales, U. D. C. A., Onatra, W., y Ambientales, U. D. C. A., et al. (2013) · Revista U D C A Actualidad & Divulgación Científica · doi:10.31910/rudca.v16.n2.2013.903 · Cited by 1
“También, se puede hablar que las hiperlipidemias son principal causa de enfermedad y muerte en pacientes diabéticos (Berglund et al. 2012).”
BackgroundDyslipidemia in Adults: How Recent Research and Recommendations Affect Nurse Practitioner Practice
Palmer, C. (2013) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2013.08.017 · Cited by 1
Early Phase Metabolic Research with Reference to Special Populations
Morrow, L., & Krentz, A. J. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_9 · Cited by 1
Serum lipid levels in adolescents and its association With type of fatty acids intake
Mohseni‐Takalloo, S., Hosseini‐Esfahani, F., Mirmiran, P., & Azizi, F. (2016) · Journal of North Khorasan University of Medical Sciences · doi:10.29252/jnkums.8.1.135 · Cited by 1
Seo, M. H. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.2.305 · Cited by 1
Marín-Sánchez, J., Sánchez, H. C. J., & Chaparro, C. M. R. (2018) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.315 · Cited by 1
CORONARY ARTERY DISEASE RISK AND LIPIDOMIC PROFILES IN FAMILIAL HYPERLIPIDEMIAS
Rämö, J. T., Ripatti, P., Tabassum, R., Söderlund, S., Matikainen, N., Gerl, M. J., Klose, C. D., Surma, M. A., Stitziel, N. O., Havulinna, A. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(19)32376-9 · Cited by 2
Khan, Z. A., Baig, K. S., Ahmad, Z., & Afridi, M. (2019) · Anaesthesia Pain & Intensive Care · doi:10.35975/apic.v23i2.1076 · Cited by 1
Case report of one month and 15 days old baby with type V hyperlipoproteinemia (HLP)
Dildar, S., & Shamsi, T. S. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-0502-0 · Cited by 1
INNOVATIONS IN DIAGNOSTICS AND TREATMENT OF PATIENTS WITH HYPERTRIGLYCERIDEMIA
Симерзин, В. В., Fatenkov, O. V., Gagloeva, I. V., Galkina, M. A., Panisheva, Y. A., & Krasovskaya, M. A. (2017) · Science and Innovations in Medicine · doi:10.35693/2500-1388-2017-0-1-43-51 · Cited by 2
Amini, A., Vaezi, Z., Koury, E., Zafar, S., & Chahla, E. J. (2020) · Cureus · doi:10.7759/cureus.9889 · Cited by 2
Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
Newman, C. B., Saunders, K. H., & Subramanian, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816569-0.00009-7 · Cited by 1
Multidisciplinary Synergy of Health Workers as an Effort to Improve Public Health Status
Yunita, E. P. (2021) · Jurnal Pengabdian Kepada Masyarakat · doi:10.22146/jpkm.40935 · Cited by 1
Acute Pancreatitis due to Hyperchylomicronemia
Duell, P. B. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-697-9_21 · Cited by 1
Association of serum triglyceride levels with the severity of acute pancreatitis
Cheng, C., Li, M., Kong, R., Xue, D., & Sun, B. (2022) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2022.01.080 · Cited by 1
Lilley, J. S., & Fazio, S. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2059-4_48 · Cited by 1
Acute Pancreatitis Due to Hyperchylomicronemia
Duell, P. B. (2021) · Contemporary Endocrinology · doi:10.1007/978-3-030-67455-7_21 · Cited by 1
Brahm, A. J., & Hegele, R. A. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_11 · Cited by 2
Thewjitcharoen, Y., Surat, K., Veerasomboonsin, V., Wattanawiroon, K., Nakasatien, S., Krittiyawong, S., & Himathongkam, T. (2022) · Clinical Medicine Insights Case Reports · doi:10.1177/11795476221119445 · Cited by 1
Analysis of Intravenous Insulin Dosing Requirements for Treatment of Severe Hypertriglyceridemia
White, B. N., Carter, B. L., & Bradford, J. L. (2022) · Hospital Pharmacy · doi:10.1177/00185787221126339 · Cited by 1
Hipertrigliceridemia grave en Argentina: prevalencia y características clínicas
Sáenz, B., Matta, M. G., Blautzik, F., Corral, A., Sampayo, F., Piedrabuena, F., & Corral, P. (2023) · Revista Argentina de Cardiología · doi:10.7775/rac.es.v91.i2.20610 · Cited by 1
“(3) La HTGG puede ser secundaria a otras patologías, como la diabetes, el abuso de alcohol, el hipotiroidismo; a situaciones fisiológicas, como el embarazo; o secundaria a fármacos, como anticonceptivos e inhibidores de la proteasa, como los más frecuentes.”
BackgroundInfluentialLipid-lowering therapy for hypertriglyceridemia-induced acute pancreatitis: Recent advances
Chen, H., Su, D.-S., Li, H., Guo, X., & Qi, X. (2023) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v31.i21.882 · Cited by 1
Patel, K., Devireddy, N., Long, C., Daya, A., Cherneskie, J., & Krill, K. L. (2024) · Cureus · doi:10.7759/cureus.51511 · Cited by 1
“Abdominal CT showed fat stranding along the anterior aspect of the pancreatic head (Figure 1 ), confirming the diagnosis of acute pancreatitis secondary to familial hypertriglyceridemia based on the Atlanta classification [3].”
BackgroundHaddad, A., Kloub, M., Abouzeid, W., Hussain, M., Haddad, D., Anwar, A., & Al-maharmeh, Q. (2024) · American Journal of Case Reports · doi:10.12659/ajcr.943858 · Cited by 2
“…is a valuable management tactic since it inhibits lipolysis and lowers the liver’s triglyceride assembly; used with fibrates to reduce TG levels, this combination can reduce TG levels by 30% to 50% while simultaneously raising HDL-C, decreasing VLDL generation, and increasing LPL synthesis [5].”
BackgroundBraun, T., Drobner, T., Kipp, K., Kiehntopf, M., Schlattmann, P., Lorkowski, S., & Dawczynski, C. (2024) · Nutrients · doi:10.3390/nu16091261 · Cited by 2
Altemeemy, I., Alibrahim, N. T. Y., Alzajaji, Q. B., & Mansour, A. A. (2024) · Cureus · doi:10.7759/cureus.67609 · Cited by 1
“The Endocrine Society and the European Atherosclerosis Society/European Society of Cardiology define severe HTG as concentrations of at least 1,000 mg/dL [4].”
BackgroundGuay, S., Gagnon, É., Paquette, M., Thériault, S., Arsenault, B. J., & Baass, A. W. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16759 · Cited by 2
Sell, J. K., & Nunez, J. J. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197812631.003.0029 · Cited by 1
Mudan, S. (2013) · Trends in Urology & Men s Health · doi:10.1002/tre.346 · Cited by 2
Dietary Patterns of Hypertriglyceridemia among Koreans Based on Food Frequency Questionnaire
Yoo, J.-E., Jun, J.-H., Kim, S., et al. (2016) · Korean Journal of Family Practice · doi:10.21215/kjfp.2016.6.2.96 · Cited by 1
Nutritional Interventions to Lower Cholesterol and Risk for Heart Disease in Children
Daniels, S. R., Hildebrandt, J., Brennan, L. K., & Couch, S. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-43027-0_12 · Cited by 1
Acute pancreatitis due to tamoxifen-induced hypertriglyceridemia
Sakakihara, I., Wato, M., OKAMOTO, K., et al. (2018) · Suizo · doi:10.2958/suizo.33.847 · Cited by 1
Kuntarattanakool, M., Isarakul, N., Tangvarasittichai, O., & Tangvarasittichai, S. (2018) · Madridge Journal of Diabetes · doi:10.18689/mjd-1000109 · Cited by 1
“While PPTG was demonstrated more potent predictor of CVD risk than fasting TG [14].”
BackgroundEffect of Soy Milk and Mung Bean Porridge on Serum Triglycerides among Postmen-opausal Women
Syailawan, F. K., Mostafa, B., & Kartikasari, L. R. (2019) · Arab Journal of Nutrition and Exercise (AJNE) · doi:10.18502/ajne.v4i1.4482 · Cited by 1
“Dietary changes are key element in the first-line management of hypertriglyceridemia [2].”
BackgroundKhyade, V. B. (2018) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.21750754 · Cited by 4
Severe Hypertriglyceridemia in the Hospitalized Patient
Mateo, R. C. I., & Ganda, O. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-38976-5_28 · Cited by 1
Effect of different degrees of hypertriglyceridemia on severity of acute pancreatitis
Jiang, J.-P., Sheng, J.-Y., & Fang, C. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i15.730 · Cited by 1
Acute Myocardial Infarction Complicated by Very Severe Hypertriglyceridemia
Wu, G., Bockman, B., & Perez, J. (2020) · Case Reports in Acute Medicine · doi:10.1159/000511065 · Cited by 1
Yulistiyanto, A. C., Hersasanti, M., Hartantyo, R. Y., Fitria, L., Chasani, A. R., & Mulyati, M. (2020) · Journal of Tropical Biodiversity and Biotechnology · doi:10.22146/jtbb.57924 · Cited by 2
“The Endocrine Society 2010 defines this as more than 150 mg/dL (Berglund et al., 2012).”
BackgroundAbdullah, T. H., Baqi, H. R., Karim, S. H., & Ghafor, D. A. (2020) · Polytechnic Journal · doi:10.25156/ptj.v10n2y2020.pp71-80 · Cited by 7
“The levels above 1000 mg/dL are considered as severe and very severe hypertriglyceridemia (Berglund et al., 2012).”
BackgroundCho, E., & Park, C. (2021) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2021.26.2.111 · Cited by 1
“HTG is classified into different severity categories: mild (serum TG levels of 150 to 199 mg/dL), moderate (200 to 999 mg/dL), severe (1,000 to 1,999 mg/dL), and very severe (≥2,000 mg/ dL).(8) While more studies are needed to define the exact TG level causing AP, AP usually occurs when the TG level is more than 1,000…”
BackgroundAcute Pancreatitis Secondary to Hypertriglyceridaemia Caused by Undiagnosed Type 2 Diabetes
Khaqan, A., Munir, A., & Haider, M. (2021) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2021.208 · Cited by 1
Pancreatitis por hipertrigliceridemia asociada a anticonceptivos orales: Reporte de un caso
Altamar, H., & Stephens, I. (2017) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.4.1.107 · Cited by 1
Baqi, H. R., Abdullah, T. H., Ghafor, D. A., et al. (2021) · Iraqi Journal of Science · doi:10.24996/ijs.2021.62.9.2 · Cited by 1
“The TG reference interval resulted from our study is 48-246 mg/dL, while the accepted normal value worldwide is below 150 mg/dL [19].”
MethodDiniz, E. T., & Bandeira, F. A. F. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_40 · Cited by 3
Metadata
- Authors
- Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H.
- Affiliations
- University of California, Davis (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- Columbia University (US)
- Harvard University (US)
- Mayo Clinic (US)
- Radboud University Medical Center (NL)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-09-01
- Volume
- 97
- Issue
- 9
- Pages
- 2969-2989
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3431581
- OpenAlex
- W2111416524
- Cited by
- 887
- References
- 206
- Citations by year
- 2026: 55 · 2025: 54 · 2024: 74 · 2023: 62 · 2022: 72 · 2021: 74 · 2020: 83 · 2019: 61 · 2018: 89 · 2017: 50 · 2016: 62 · 2015: 57 · 2014: 48 · 2013: 41
- FWCI
- 47.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- American Heart Association
- European Society of Endocrinology
- National Heart, Lung, and Blood Institute (R01HL045095)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypertriglyceridemia, triglyceride levels, fasting triglycerides, cardiovascular risk, pancreatitis, secondary hyperlipidemia, familial hypertriglyceridemia, dyslipidemia, non-HDL cholesterol, lifestyle therapy, fibrate therapy
- MeSH terms
- Exercise Therapy, Humans, Terminology as Topic, Triglycerides, Hypertriglyceridemia, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.